Influenza Activity and Composition of the 2022–23 Influenza Vaccine — United States, 2021–22 Season
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm7129a1
- PMID
- 35862284
- PMCID
- PMC9310632
- OpenAlex
- W4286488929
- Study type
- Journal article
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The report informs the composition of the 2022–23 Northern Hemisphere influenza vaccine and emphasizes continued vigilance for influenza infections, including novel influenza A viruses, particularly given an ongoing highly pathogenic avian influenza A(H5N1) outbreak. Annual seasonal influenza vaccination remains the best protection against seasonal influenza and its potentially severe consequences.
Structured evidence summary
Research question
This surveillance report describes influenza activity patterns in the United States during the 2021–22 season and presents the composition of the Northern Hemisphere 2022–23 influenza vaccine.
Study design
Surveillance summary covering October 3, 2021 through June 11, 2022, monitoring influenza activity in the United States.
Population and setting
United States population during the 2021–22 influenza season.
Main findings
Influenza activity began increasing in November 2021 and remained elevated until mid-June 2022, displaying two distinct waves with A(H3N2) viruses predominating throughout the season. This pattern differed from typical pre-COVID-19 seasons, when activity usually began in fall and peaked in February.
Public-health relevance
The report informs the composition of the 2022–23 Northern Hemisphere influenza vaccine and emphasizes continued vigilance for influenza infections, including novel influenza A viruses, particularly given an ongoing highly pathogenic avian influenza A(H5N1) outbreak. Annual seasonal influenza vaccination remains the best protection against seasonal influenza and its potentially severe consequences.
Important limitations
This summary is limited to the supplied single-article abstract and metadata and requires the original paper for decision-grade interpretation of surveillance methodology, case definitions, and completeness of data collection.
GIDS interpretation
This article was identified through classifier links to influenza, COVID-19, H5N1, outbreak investigation, surveillance, and vaccination topics for the United States, supporting its discoverability in systems monitoring respiratory pathogen activity and vaccine composition decisions.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 14 auditable classifier relationships to diseases, places, topics, and study design.